PMID- 33324549
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Outcomes for Surgery in Stage IA Large Cell Lung Neuroendocrine Compared With 
      Other Types of Non-Small Cell Lung Cancer: A Propensity Score Matching Study 
      Based on the Surveillance, Epidemiology, and End Results (SEER) Database.
PG  - 572462
LID - 10.3389/fonc.2020.572462 [doi]
LID - 572462
AB  - BACKGROUND: Pulmonary large cell neuroendocrine cancer (LCNEC) is commonly 
      classified as non-small cell lung cancer (NSCLC). Even for stage I disease, after 
      surgery the survival is always poor, but clinical research on LCNEC is scant and 
      always with unsatisfying sample sizes. Thus, we conduct the first study using the 
      Surveillance, Epidemiology, and End Results (SEER) database to compare survival 
      after surgery between stage I LCNEC and other types of NSCLC. METHODS: From 2004 
      to 2016, 473 patients with stage IA LCNEC, 17,669 patients with lung 
      adenocarcinoma (LADC) and 8,475 patients with lung squamous cell cancer (LSCC), 
      all treated with surgery were identified. In addition, 1:1 PSM was used, and 
      overall (OS) and cancer-specific survival (CSS) between groups were compared. 
      RESULTS: The 5-year OS rates and CSS rates for LCNEC were 52.5% and 81.5%, 
      respectively. Overall, both OS and CSS were significantly superior for stage IA 
      LADC than LCNEC (for OS: HR 0.636, 95% CI 0.568-0.712; for CSS: HR 0.688, 95% CI 
      0.561-0.842, LCNEC as reference), while comparable for LSCC with LCNEC (for OS: 
      HR 0.974, 95% CI 0.869-1.091; for CSS: HR 0.907, 95% CI 0.738-1.115). PSM 
      generated 471 pairs when LCNEC was compared with LADC and both OS and CSS were 
      significantly better in LADC than LCNEC (for OS: HR 0.580, 95% CI 0.491-0.686; 
      for CSS: HR 0.602, 95% CI 0.446-0.814). Of note, for the subgroup of patients </= 
      65 years old, HRs for both OS and CSS were lower (for OS: HR 0.470; for CSS: HR 
      0.482). As for comparison between LCNEC and LSCC, PSM generated 470 pairs. 
      Differently, only CSS was significantly superior in LSCC than LCNEC (HR 0.563, 
      95% CI 0.392-0.807), while OS was not. Further grouping by age showed only CSS 
      between two groups for patients with age </= 65 years old was significantly 
      different (P = 0.006). CONCLUSIONS: We report the first survival comparison after 
      surgery between stage IA LCNEC and other types of NSCLC by SEER database and PSM. 
      Our results demonstrated after surgery, stage IA LCNEC was worse in survival, 
      especially compared to LADC. Extra clinical care should be paid, especially for 
      younger patients. More studies investigating adjuvant therapy are warranted.
CI  - Copyright (c) 2020 Zou, Guo, Ye, Zhou, Chu, Chu, Ni, Zhu and Yang.
FAU - Zou, Liqing
AU  - Zou L
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan 
      University, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Guo, Tiantian
AU  - Guo T
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan 
      University, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Ye, Luxi
AU  - Ye L
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan 
      University, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Zhou, Yue
AU  - Zhou Y
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan 
      University, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Chu, Li
AU  - Chu L
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan 
      University, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Chu, Xiao
AU  - Chu X
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan 
      University, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Ni, Jianjiao
AU  - Ni J
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan 
      University, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
AD  - Institute of Thoracic Oncology, Fudan University, Shanghai, China.
FAU - Zhu, Zhengfei
AU  - Zhu Z
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan 
      University, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
AD  - Institute of Thoracic Oncology, Fudan University, Shanghai, China.
FAU - Yang, Xi
AU  - Yang X
AD  - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan 
      University, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20201126
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7727448
OTO - NOTNLM
OT  - SEER database
OT  - large cell lung neuroendocrine
OT  - propensity score matching
OT  - stage IA
OT  - surgery
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
PMCR- 2020/01/01
CRDT- 2020/12/16 05:37
PHST- 2020/06/14 00:00 [received]
PHST- 2020/10/23 00:00 [accepted]
PHST- 2020/12/16 05:37 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.572462 [doi]
PST - epublish
SO  - Front Oncol. 2020 Nov 26;10:572462. doi: 10.3389/fonc.2020.572462. eCollection 
      2020.